SEC Form 4 · accession 0000882104-17-000125
PDL BIOPHARMA, INC. · PDLI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steffen Pietzke
Officer — VP, Finance and CAO
Period of report
Dec 15, 2017
Accepted (ET)
Dec 19, 2017 · 8:03 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882104
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stockF1 | Dec 15, 2017 | D | 5,513 | $0.00 | D | 139,587 | D | |
| Common stock | holding | — | — | — | 20,590 | I | Held by Spouse |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Disposition of common stock due to performance criteria not being achieved under equity incentive plans.